Astrana Health, Inc. (ASTH)
(Delayed Data from NSDQ)
$39.96 USD
-0.01 (-0.03%)
Updated May 28, 2024 04:00 PM ET
After-Market: $39.99 +0.03 (0.08%) 4:50 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ASTH 39.96 -0.01(-0.03%)
Will ASTH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ASTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASTH
Here is Why Growth Investors Should Buy Astrana Health, Inc. (ASTH) Now
DaVita HealthCare (DVA) Surpasses Q1 Earnings and Revenue Estimates
ASTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Option Care (OPCH) Q1 Earnings and Revenues Surpass Estimates
Astrana Health Inc. (ASTH) Q4 Earnings and Revenues Top Estimates
Other News for ASTH
Astrana Health, Inc. to Participate in Upcoming Investor Conferences
ASTH Stock Earnings: Astrana Health Beats EPS, Misses Revenue for Q1 2024
Astrana Health Shares Financial Overview with Investors
Astrana Health, Inc. to Participate in Upcoming Investor Conference
Stifel Nicolaus Reaffirms Their Buy Rating on Astrana Health (ASTH)